Head-to-head · Value Score
Vitara RX vs Obu Health
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Obu Health a 70. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameObu Health
#246 · Grade C · Watch List
Est. first month
From $190/mo (starting dose, plus a separate fee, compounded)
Save ~86% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 70 — an est. $99/mo first month, with no teaser step-up baked in. Obu Health isn't out of it: Shoppers who want compounded GLP-1 plus peptide add-ons with named 503A pharmacies.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Obu Health |
|---|---|---|
| Value Score | 91 (A) | 70 (C) |
| Est. first month | $99/mo | From $190/mo (starting dose, plus a separate fee, compounded) |
| Save vs brand-name | ~93% | ~86% |
| Semaglutide | $99/mo | From $190/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $149/mo | From $239/mo (starting dose, plus a separate fee, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Obu Health
Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons.
Why it's a deal
- LegitScript-certified with publicly displayed ID (44206977)
- Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
- Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
- Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
- 24-hour US board-certified physician response window
The fine print
- Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
- No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
- Medical director not named publicly
- No published consultation fee disclosure — unclear whether physician visit is included in medication price
- All sales final per FAQ ('Federal and State law do not allow medication returns')
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Obu Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.